|
AU2013206293A1
|
|
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
AU2009210387A1
|
|
Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use
|
|
AU2008201991A1
|
|
Therapeutic Polypeptides, Nucleic Acids Encoding Same and Methods of Use
|
|
AU2008201989A1
|
|
Method of Detecting and Treating Tuberous Sclerosis Complex Associated Disorders
|
|
WO2008133641A2
|
|
Antibodies directed to gpnmb and uses thereof
|
|
AU2007202935A1
|
|
Proteins Named FCTRX and Nucleic Acids Encoding Same
|
|
AU2007202435A1
|
|
Treatment of Inflammatory Bowel Disease Using Growth Factors
|
|
WO2007146160A2
|
|
Methods for the treatment of renal disease using anti-pdgf-dd antibodies
|
|
WO2007109307A2
|
|
Antibodies directed to angiopoietin-like protein 4 and uses thereof
|
|
WO2007065037A2
|
|
Antibodies against mmp-13 (collagenase-3) and uses thereof
|
|
WO2007059234A1
|
|
Method for the treatment of pdgf-d related diseases using anit-pdgf-dd antibodies
|
|
CA2629453A1
|
|
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
AU2006225276A1
|
|
Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis
|
|
AU2006201467A1
|
|
Growth Factor Polypeptides and Nucleic Acids Encoding Same
|
|
WO2007106056A1
|
|
Compositions and methods for treating t-cell mediated pathological conditions
|
|
AU2005248940A1
|
|
Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
|
|
AU2005306898A1
|
|
Formulations, methods of production and uses of FGF-20
|
|
WO2006034007A2
|
|
Methods of treating metabolic disorders by modulation of salt-inducible serine/threonine kinase 2
|
|
AU2005203590A1
|
|
Novel sphingosine kinases
|
|
WO2005094365A2
|
|
Ten-m3 polypeptides and polynucleotides and their methods of use
|
